leadf
logo-loader
RNS
viewReNeuron Group PLC

ReNeuron Group plc - Analyst Conference Call

RNS Number : 6829K
ReNeuron Group plc
06 January 2021
 

 

 

6 January 2021

 

 

AIM: RENE.L

RNS REACH

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

 Analyst Conference Call

 

ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, will host a conference call for analysts at 10.00am GMT today to discuss the Company's recent half year results,  fundraising and outlook for the year ahead. 

Analysts who require dial-in details, please contact Buchanan at reneuron@buchanan.uk.com.

A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 6 January 2021 at this link:

https://webcasting.buchanan.uk.com/broadcast/5fd23c59ca22cd76f9d3c662 

The recorded webcast will also be made available at the investor centre of ReNeuron's website, http://www.reneuron.com/investors/investor-centre/.

ENQUIRIES:

 

ReNeuron

 +44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan (UK Media/Investor relations)

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham


 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

 

+44 (0) 20 7710 7600



N+1 Singer (Joint Broker)

Aubrey Powell, James Moat, Hannah Woodley

 

+44 (0) 20 7496 3000

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.  

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUVRWRARUARAR

Quick facts: ReNeuron Group PLC

Price: -

Market: LSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

3 min read